Healthcare - Press Releases

  • 1085 Press Releases ยท
  • RSS
Published on Mon 17 Mar 2025 4:06:07 UTC
SILVER SPRING, Md., March 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
Published on Mon 17 Mar 2025 4:06:05 UTC
DENVER, March 14, 2025 /PRNewswire/ -- Espire Dental, a fast-growing, elite, cosmetic and multi-specialty group practice, founded by dentists, is pleased to announce a new partnership with Zollege, which operates Dental Assistant Schools throughout the state which are approved and regulated by the Colorado Department of Higher Education, Private Occupational School Board. This new collaboration expands access to a 12-week, hands-on training Dental Assisting Program that prepares aspiring dental assistants for rewarding careers without the burden of heavy student debt.
Published on Mon 17 Mar 2025 4:06:03 UTC
GAINESVILLE, Fla, March 14, 2025 /PRNewswire/ -- iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, today announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi's capabilities in developing cutting-edge immunotherapies for solid tumors.
Published on Mon 17 Mar 2025 4:05:58 UTC
SIMI VALLEY, Calif., March 14, 2025 /PRNewswire/ -- Adventist HealthSimi Valley is proud to announce the opening of its newly designed clinic, a major step forward in providing high-quality, accessible healthcare to the community.This new facility combines two former clinics into one streamlined location, increasing efficiency, improving patient flow, and expanding access to primary and specialty care.
Published on Mon 17 Mar 2025 4:05:51 UTC
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress in Prague, Czech Republic.
Published on Mon 17 Mar 2025 4:05:34 UTC
The Series C financing was led by a global strategic investor along with participation from new investors Aphelion Cardeation and Unorthodox Ventures. Existing investors Engage Venture Partners, JWC Venture and Features Capital also participated in the round. Laplace Interventional plans to use the funds raised from this round towards completing their Early Feasibility Study (EFS) and work towards a pivotal study approval.
Published on Mon 17 Mar 2025 4:05:29 UTC
PERTH, Australia, March 16, 2025 /PRNewswire/ -- ArgentBioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA, a novel anti-inflammatory treatment. The study confirmed CimetrA's strong safety profile and demonstrated faster recovery times in COVID-19 patients.
Published on Mon 17 Mar 2025 4:05:26 UTC
CANTON, Conn., March 17, 2025 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a manufacturer of custom cranial implants, has announced its financial results for the year ended December 31, 2024.
Published on Mon 17 Mar 2025 4:04:00 UTC
NORTH CHICAGO, Ill., March 15, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator's choice (IC) chemotherapy.1 Ovarian cancer patients often present with late-stage disease and are historically first treated with platinum-based chemotherapy, which they may become resistant to and require another therapy, such as ELAHERE.2
Published on Mon 17 Mar 2025 4:03:42 UTC
SIMI VALLEY, California, 15 de marzo de 2025 /PRNewswire-HISPANIC PR WIRE/ -- Adventist Health Simi Valley se enorgullece en anunciar la apertura de su clnica de nuevo diseo, un gran paso adelante para proporcionar atencin mdica accesible y de alta calidad a la comunidad.Esta nueva instalacin combina dos clnicas anteriores en una ubicacin simplificada, lo que aumenta la eficiencia, mejora el flujo de pacientes y ampla el acceso a la atencin primaria y especializada.
Published on Mon 17 Mar 2025 4:02:51 UTC
HONG KONG, March 16, 2025 /PRNewswire/ --Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy.
Published on Mon 17 Mar 2025 3:55:36 UTC
Structured Coaching Helps Energy Healers Overcome Industry Challenges and Build Sustainable Practices
Published on Mon 17 Mar 2025 3:55:20 UTC
NEW YORK, March 15, 2025 /PRNewswire/ --The official brand behind Prime Biome, a product developed under Bioventra's portfolio of advanced formulations, has issued a public advisory regarding unauthorized third-party resellers misrepresenting the product online. Reports indicate that unverified vendors online have been listing non-official versions of Prime Biome across various platforms, leading to confusion among consumers.
Published on Mon 17 Mar 2025 3:54:24 UTC
A featured presentation will be "Enhance Patient Safety With Privacy-Preserving AI:Multimodal DNN and VLM for Event Detection in Healthcare."
Published on Fri 14 Mar 2025 8:27:09 UTC
SHELTON, Conn., March 13, 2025 /PRNewswire/ --Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces 2024 year-end financial results and provides a corporate update.
Published on Fri 14 Mar 2025 8:27:05 UTC
COCONUT GROVE, Fla., March 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has rescheduled the release of its financial results for the full-year ended December 31, 2024, to before market open on March 24, 2025.
Published on Fri 14 Mar 2025 8:27:00 UTC
RA'ANANA, Israel, March 13, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.
Published on Fri 14 Mar 2025 8:26:58 UTC
FORT WORTH, Texas, March 13, 2025 /PRNewswire/ --According toCDC, more than 222 measles cases have been reported across 12 states as of this press release.
Published on Fri 14 Mar 2025 8:26:55 UTC
As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion.
Published on Fri 14 Mar 2025 8:26:52 UTC
SAN FRANCISCO, March 13, 2025 /PRNewswire/ -- Hyde Park Capitalannounced today that its client, Infiniti Medical LLC(and its subsidiary Orthomed UK Ltd), two globally recognized brands specializing in veterinary interventional radiology, cardiology, soft tissue surgery, and orthopedics,has been acquired by Creative Science, a CIMA Animal Healthcompany, and a leader in veterinary medical solutions. CIMA Animal Health, a portfolio company of Incline Equity Partners, is dedicated to improving the lives of animals and those who care for them. Hyde Park Capital, led by Managing Director Craig Lawson, served as the exclusive financial advisor to Infiniti Medical for this transaction.
Published on Fri 14 Mar 2025 8:26:49 UTC
A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landscape with actionable market intelligence
Published on Fri 14 Mar 2025 8:26:42 UTC
PORTLAND, Ore, March 13, 2025 /PRNewswire/ -- Ann Sacks, an industry leader in luxury tile and stone, is pleased to announce the opening of its latest showroom and slab gallery, Ann Sacks Charlotte, 721 Gov Morrison Street, Unit 110A, Charlotte, NC 28211, phone number (980) 316-3996. The Ann Sacks Showroom and Slab Gallery is open Monday through Friday, 9:00 a.m. to 5:00 p.m., and Saturdays by appointment. Catering to designers and consumers seeking out the finest in home furnishings, South Park was a natural fit for Ann Sacks Charlotte and the range of brands one can experience under its roof.
Published on Fri 14 Mar 2025 8:26:35 UTC
PLYMOUTH MEETING, Pa., March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19. In the trial, 100% (24/24) of participants who have reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production. Notably, no participant developed anti-drug antibodies (ADA), a common challenge observed in other gene-based delivery platforms, such as adeno-associated virus (AAV) mediated antibody expression. Additionally, the DMAbs were well tolerated, with the most common side effects being mild, temporary injection site reactions, such as pain and redness. The trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the Perelman School of Medicine at the University of Pennsylvania.
Published on Fri 14 Mar 2025 8:26:28 UTC
DALLAS, March 13, 2025 /PRNewswire/ --Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the H.C. Wainwright 3rd Annual BioConnect Showcase, taking place March 16-18, 2025, on Kiawah Island, SC. Details for the presentation are as follows:
Published on Fri 14 Mar 2025 8:26:20 UTC
SEATTLE, March 13, 2025 /PRNewswire/ --Washington Poison Center (WAPC), Washington's nonprofit service for free medical advice on poisoning and drug overdoses, is pleased to announce the four winners of its 19th annual Poison Prevention Poster Contest: